Italy
Published on: Thu, 13 Dec 2018
Following a request from the European Commission, EFSA was asked to review the comments received on the Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the scientific substantiation of a health claim related to Symbiosal® and lowering of blood pressure and reduced risk of hypertension pursuant to Article 14 of Regulation (EC) No 1924/2006. Comments originating from the applicant (Han‐Biotech GmbH) were submitted to EFSA via the European Commission Services. EFSA has reviewed the comments with the contribution of the chair of the NDA Working Group on Claims, the chair of the NDA Panel and the Working Group on Claims. In its opinion adopted on 27 June 2018, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) concluded that a cause and effect relationship has not been established between the consumption of Symbiosal® and lowering of blood pressure. The comments received do not require any change in the conclusions of the NDA Panel.
© European Food Safety Authority, 2015
